Healthcare
Monopar Therapeutics Inc.(MNPR)
Live Price
Offline$67.47
+4.78% today
1Y Change
+92.58%
Window
Jun 25, 2025 β Jun 15, 2026
- Market Cap
- $360.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -36.0%
- Dividend Yield
- 0.0%
Coverage: 244 bars Β· Jun 25, 2025 β Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Monopar Therapeutics Inc. (MNPR) is a Healthcare stock with a market cap of $360.00M and listed on NASDAQ. The stock last traded around $67.47 and up 92.6% across the available one-year price window (Jun 25, 2025 β Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -36.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -36.0%, free cash flow -190422.0% with operating margin 0.0% and ROIC -0.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MNPR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -36.0%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.1% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | β | +0.1% | -10.0% | -3.1% |
2026 Mar 27, 2026 | -19.1% | -1.5% | -0.8% | -0.1% |
2025 Nov 13, 2025 | -4.3% | -10.4% | -4.6% | -14.3% |
Benchmark Edge
MNPR vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MNPR
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MNPR Max Drawdown
-50.89%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MNPR and SPY.
Company Overview
Monopar Therapeutics Inc.
NASDAQ Capital Market
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo EspaΓ±ol de InvestigaciΓ³n en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
- Leadership
- Chandler D. Robinson
- IPO Date
- Dec 19, 2019
- Employees
- 14
- Street Address
- 1000 Skokie Boulevard
- Mailing
- Wilmette, IL, 60091
- Region
- Wilmette, IL, US
- Reporting Currency
- USD
- Investor Line
- 847 388 0349
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- 4016.3
- Price/Sales
- β
- Price/Book
- 0.0
Growth
- Revenue
- 0.0%
- EPS
- -36.0%
- Free Cash Flow
- -190422.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -0.0%
- ROIC
- -0.0%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 51.35
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.